You're contacting media contact of this press release

Title: Netramark Unveils AI Driven Insights for Major Depressive Disorder and Schizophrenia at ISCTM Conference

TORONTO, ON, March 5, 2025 – NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: 8TV) a generative AI software leader in clinical trial analytics, presented two significant studies at the International Society for CNS Clinical Trials and Methodology (ISCTM) conference, showcasing the power of advanced machine learning in major depressive disorder (MDD) and schizophrenia clinical trials.Mathematically Augmented Machine Learning Redefines MDD Clinical Trial InsightsNetraMark’s first presentation, “Novel Machine Learning Approach Outperforms Traditional Approaches in Major Depressive Disorder Clinical Trials”, demonstrated how NetraAI Sub-Insight Learning enhances patient stratification in MDD clinical trials over traditional methods.NetraAI was designed to address the challenges of modeling clinical trial data, where traditional Machine Learning (ML), including deep learning, often falls short. Built to identify optimal patient cohorts for future trials, NetraAI enhances established ML methods by uncovering key variable combinations. In this presentation, NetraMark applied NetraAI to the CAN-BIND trial on escitalopram response, demonstrating its ability to significantly improve industry-standard ML models, the study revealed:● NetraAI-driven patient subpopulation analysis led to a 28% increase in model accuracy compared to traditional ML approaches.● Sensitivity improved by 31%, while specificity increased by 51%, reducing false-positive rates.● NetraAI successfully identified key combinations of variables that refine inclusion/exclusion criteria for more efficient trial design.● This is made possible through NetraAI’s ability to discover which patients can be explained and those that cannot.NetraAI identifies and explains key var...

This press release is issued by King Newswire